Encyclopedia entry
Survodutide (UK): GLP-1/glucagon dual-agonist under investigation
Oliver Mackman · Editorial director · Best Business Loans Ltd (16833937)
Last updated 2026-06-16
Editorial with affiliate links. We earn from purchases via outbound retailer / clinic links. How we are funded.
AI-friendly summary · Survodutide
Survodutide (Boehringer Ingelheim and Zealand Pharma research code BI 456906) is a synthetic peptide that targets two receptors: GLP-1 and glucagon. The glucagon-receptor component distinguishes it from licensed GLP-1 agonists and from the GLP-1/GIP dual agonist tirzepatide, and is central to its research in metabolic liver disease (MASH). As of June 2026 it is in Phase III trials and has not been approved by the MHRA, FDA, or EMA. It cannot be prescribed in the UK. UK research-peptide retailers sell it under research-use-only framing.
Top UK Survodutide retailers
Mechanism of action
How Survodutide works
Survodutide is a long-acting synthetic peptide engineered to act as a dual agonist at the GLP-1 (glucagon-like peptide-1) receptor and the glucagon receptor. The GLP-1 component drives the appetite and glycaemic effects familiar from the incretin class. The glucagon-receptor component is hypothesised in the clinical literature to increase energy expenditure and to act on hepatic lipid metabolism, which is the rationale for the compound's prominent research programme in metabolic dysfunction-associated steatohepatitis (MASH). This dual profile differs from tirzepatide, which combines GLP-1 with GIP rather than glucagon. The integrated mechanism remains the subject of ongoing pharmacological characterisation.
Source: Zealand Pharma and Boehringer Ingelheim Phase II obesity and MASH programmes (2024)
What it is
Survodutide (also known by the research identifier BI 456906) is a long-acting injectable peptide. Its dual GLP-1/glucagon mechanism distinguishes it from single GLP-1 agonist semaglutide and from the GLP-1/GIP dual agonist tirzepatide. The glucagon-receptor agonism underpins its research in obesity and in metabolic liver disease (MASH).
- · Developers: Boehringer Ingelheim and Zealand Pharma.
- · Mechanism: dual agonism at the GLP-1 receptor and the glucagon receptor.
- · Format: once-weekly subcutaneous injection in clinical trial settings.
- · Lead research indications: obesity and metabolic dysfunction-associated steatohepatitis (MASH).
- · Status: Phase III clinical development. No regulatory approval in any country as of June 2026.
- · Research identifier: BI 456906.
Clinical development status
Survodutide Phase II results were published in 2024 for two indications: an obesity trial reported in The Lancet, and a metabolic dysfunction-associated steatohepatitis (MASH) trial reported in the New England Journal of Medicine. The trials reported weight and liver-histology endpoints across dose cohorts. Phase III trials are ongoing as of June 2026. PeptideClear does not republish specific efficacy figures as recommendations. Readers should consult the original publications for the reported data.
- · Phase II obesity: results published in The Lancet 2024.
- · Phase II MASH: results published in the New England Journal of Medicine 2024.
- · Phase III: programme ongoing. Results not yet published as of June 2026.
- · No published peer-reviewed head-to-head data against tirzepatide or retatrutide as of June 2026.
All claims above are sourced from published peer-reviewed clinical trial data. PeptideClear does not extrapolate from trial data to individual outcomes.
UK regulatory framing
Important: not licensed for use in the UK
Survodutide is not currently licensed by the MHRA, FDA, or EMA. It is not a prescribable medicine in the UK and cannot be supplied by any UK pharmacy. It is not the same as Mounjaro (tirzepatide) or Wegovy (semaglutide), which are MHRA-licensed medicines available via UK prescribers. Do not use any survodutide product without consultation with a UK-licensed prescriber. Research-tier supply does not substitute for a licensed medical product.
- · Not a controlled drug under the Misuse of Drugs Act 1971.
- · Not scheduled under the Psychoactive Substances Act 2016.
- · No UK marketing authorisation as a medicine. Phase III trials are ongoing; no regulatory approval has been granted.
- · Sold legally as a research chemical when marketed without health or therapeutic claims.
- · Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
- · The supply chain for research-tier survodutide is distinct from the manufacturers' clinical trial supply. Purity, source, and authenticity cannot be verified by the buyer through any public mechanism.
Risks and unknowns
What the literature does not yet show about Survodutide
Known concerns
- No regulatory approval anywhere as of June 2026. The full Phase III safety dataset is not yet published in peer-reviewed form.
- Retail research-peptide supply chain is not connected to pharmaceutical-grade manufacturing by Boehringer Ingelheim or Zealand Pharma. Purity and authenticity cannot be publicly verified.
- The published Phase II trials used a structured dose-titration protocol under medical supervision. The gastrointestinal-effect profile reported in the trial literature is present in the molecule regardless of jurisdiction.
- Glucagon-receptor agonism is a less-precedented mechanism in licensed medicine than GLP-1 agonism alone, so the long-term safety reference base is narrower.
Open questions in the literature
- Long-term cardiovascular and hepatic outcomes of sustained dual GLP-1/glucagon agonism are not established. Phase III outcome data is not yet reported.
- Whether the glucagon-receptor component delivers clinically meaningful added benefit over GLP-1/GIP agonists in head-to-head comparison is not established.
- Pharmacokinetics of research-tier supply versus the manufacturers' clinical-trial product are not publicly characterised.
- Effects in populations excluded from the trial programme are not established.
Regulatory note
No UK marketing authorisation. Not a controlled drug under the Misuse of Drugs Act 1971. Not approved by any regulator as of June 2026. Phase III trials ongoing. Becomes an unlicensed medicinal product the moment a retailer or commentator makes therapeutic claims about it.
Important: PeptideClear publishes encyclopedia commentary only and does not recommend human use. Speak to a UK-registered prescriber before any medical decision.
Adjacent compounds under investigation
Survodutide is one of several next-generation compounds under active clinical investigation in the metabolic and obesity space. Adjacent compounds researchers may encounter in the same context:
- · Retatrutide: an Eli Lilly GLP-1/GIP/glucagon triple-agonist. Adds GIP to the glucagon and GLP-1 receptors.
- · Cagrilintide: a Novo Nordisk long-acting amylin analogue, studied with semaglutide as CagriSema. Different (amylin) pathway.
- · Tesamorelin: a GHRH analogue studied for visceral fat, a different mechanism again.
All of these compounds are unlicensed in the UK as of June 2026 and are available outside clinical trials only through research-peptide retailers under research-use-only framing.
Supply quality: why CoA practice matters more here
For well-characterised research peptides such as BPC-157 or TB-500, multiple UK retailers have years of customer feedback and established supply relationships. For survodutide, the compound is complex to synthesise correctly, the Phase III data has not been published, and no pharmaceutical-grade UK supply exists outside clinical trials.
- · CoA (Certificate of Analysis) practice is the only public quality signal available. Retailers who publish CoAs via open subdomains or verifiable QR codes provide more accountability than those who gate CoAs behind email requests or do not publish them.
- · Named lab partners provide more recourse than unnamed "third-party" claims.
- · Our UK retailers comparison ranks research peptide retailers on CoA transparency, trading tenure, and corporate identity.
Where to learn more
- · PubMed search: Survodutide returns the Phase II obesity and MASH data.
- · PubMed: BI 456906 for the research-code literature.
- · ClinicalTrials.gov: Survodutide for the Phase III trial records.
- · UK retailer purity comparison: research peptides UK retailers.
Frequently asked questions
Is Survodutide legal in the UK?
What does the human evidence show for Survodutide?
What is the regulatory status of Survodutide in the UK?
How is Survodutide different from tirzepatide?
Where can I learn more about Survodutide?
UK retailers stocking Survodutide
A small number of UK research-peptide retailers stock survodutide. PeptideClear compares them on CoA transparency, trading tenure, and operator identity. Research use only.
Compare UK retailersPopular on PeptideClear
Ready to buy
Buy Survodutide in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.